

The PRISMAP Radiolanthanides Workshop



Report of Contributions

Contribution ID: 1

Type: **not specified**

Production and application of radiolanthanides at TRIUMF

Presenter: SCHAFFER, Paul (TRIUMF)

Contribution ID: 2

Type: **not specified**

Studies of different production paths of ^{155}Tb on Gd targets: from target manufacturing to Tb/Gd separation

Presenter: Dr SOUNALET, Thomas (Arronax)

Contribution ID: 3

Type: **not specified**

Cross-section measurements towards an optimized production of theranostic radionuclides at the Bern Medical Cyclotron

Presenter: BRACCINI, Saverio (University of Bern)

Contribution ID: 4

Type: **not specified**

Nuclear data measurement of lanthanides

Presenter: JUGET, Frédéric J (IRA)

Contribution ID: 5

Type: **not specified**

Decay data: the importance and impact of metrology

Presenter: Dr COLLINS, Sean (NPL)

Contribution ID: 6

Type: **not specified**

Advancing Auger electron therapy: Developing methods for high-resolution spectral characterization of radioisotopes

Presenter: MAUGERI, Emilio Andrea (PSI - Paul Scherrer Institut)

Contribution ID: 7

Type: **not specified**

Tb radionuclides for imaging and therapy: How far have we progressed?

Presenter: VAN DER MEULEN, Nicholas Philip (PSI - Paul Scherrer Institut)

Contribution ID: 8

Type: **not specified**

Production and radiochemical processing of medical radiolanthanides

Presenter: Dr VAN DE VOORDE, Michiel (SCK-CEN)

Contribution ID: 9

Type: **not specified**

Production of novel medically relevant radiolanthanides at Paul Scherrer Institute

Presenter: TALIP, Zeynep (PSI - Paul Scherrer Institut)

Contribution ID: **10**

Type: **not specified**

Mass separation of stable and radioactive lanthanide isotopes

Presenter: Dr KÖSTER, Ulli (ILL)

Contribution ID: 11

Type: **not specified**

Impact-TATTOOS-Novel radionuclides production in Switzerland: A design status report

Presenter: EICHLER, Robert (PSI - Paul Scherrer Institut)

Contribution ID: 12

Type: **not specified**

High-purity radionuclides at ISOL@MYRRHA

Presenter: Dr POPESCU, Lucia (SEK-CEN)

Contribution ID: 13

Type: **not specified**

CERN-MEDICIS: Experience of mass-separation with radiolanthanides towards their clinical translation

Presenter: Dr STORA, Thierry (CERN)

Contribution ID: 14

Type: **not specified**

Dosimetric comparison of the radiolanthanides 177Lu and 161Tb for cancer therapies with radiopharmaceuticals

Presenter: Dr BERNHARDT, Peter (Gothenburg University)

Contribution ID: 15

Type: **not specified**

^{161}Tb a promising radionuclide for early TRT: absorbed doses compared to ^{177}Lu in micrometastases, cell clusters, and single tumour cells

Presenter: Dr HINDIÉ, Elif ((CHU-Bordeaux))

Contribution ID: 16

Type: **not specified**

Dose-response effects of the additional Auger and IC electrons of ^{161}Tb -vs ^{177}Lu -labelled agonists and antagonists

Presenter: Dr KOOLE, Michel (KU Leuven)

Contribution ID: 17

Type: **not specified**

Development of ^{161}Tb and ^{153}Sm based radiopharmaceuticals

Presenter: Dr OOMS, Maarten (SCK-CEN)

Contribution ID: **18**

Type: **not specified**

Preclinical studies of subcellular targeted 161Tb-complexes for cancer radiotheranostics

Presenter: Dr ROCHA PAULO, Antonio (IST-ID)

Contribution ID: 19

Type: **not specified**

Production of Radiolanthanides for medical applications in the USA

Presenter: ELLISON, Paul (University of Wisconsin Madison)

Contribution ID: 20

Type: **not specified**

Hybrid hydroxypyridinone-macrocyclic chelators for coordination of lanthanide and actinide radionuclides

Presenter: MA, Michelle (School of Biomedical Engineering and Imaging Sciences, King's College London)

Contribution ID: 21

Type: **not specified**

161Tb therapies for clinical trials-experiences

Presenter: SCHMID, David (PSI)

Contribution ID: 22

Type: **not specified**

Radiolanthanides in the pharmaceutical regulatory framework in Europe

Presenter: Dr DECRISTOFORO, Clemens (MUI)

Contribution ID: 23

Type: **not specified**

A regulator perspective on clinical trials using new radionuclides

Presenter: Dr SENN, Anna C. (FOPH)

Contribution ID: 24

Type: **not specified**

Preclinical Development of ^{161}Tb -based Radiopharmaceuticals for Radioligand Therapy

Presenter: Dr MÜLLER, Cristina (PSI)